PT2419741T - Avaliação de risco para tratamento com antibióticos em pacientes que sofrem de doença não infeciosa primária através da determinação do nível de procalcitonina - Google Patents

Avaliação de risco para tratamento com antibióticos em pacientes que sofrem de doença não infeciosa primária através da determinação do nível de procalcitonina

Info

Publication number
PT2419741T
PT2419741T PT107175317T PT10717531T PT2419741T PT 2419741 T PT2419741 T PT 2419741T PT 107175317 T PT107175317 T PT 107175317T PT 10717531 T PT10717531 T PT 10717531T PT 2419741 T PT2419741 T PT 2419741T
Authority
PT
Portugal
Prior art keywords
procalcitonin
determining
level
infectious disease
risk assessment
Prior art date
Application number
PT107175317T
Other languages
English (en)
Inventor
Bergmann Andreas
Struck Joachim
Original Assignee
Brahms Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40886944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2419741(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Brahms Gmbh filed Critical Brahms Gmbh
Publication of PT2419741T publication Critical patent/PT2419741T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT107175317T 2009-04-14 2010-04-14 Avaliação de risco para tratamento com antibióticos em pacientes que sofrem de doença não infeciosa primária através da determinação do nível de procalcitonina PT2419741T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09157886 2009-04-14

Publications (1)

Publication Number Publication Date
PT2419741T true PT2419741T (pt) 2019-11-04

Family

ID=40886944

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107175317T PT2419741T (pt) 2009-04-14 2010-04-14 Avaliação de risco para tratamento com antibióticos em pacientes que sofrem de doença não infeciosa primária através da determinação do nível de procalcitonina

Country Status (15)

Country Link
US (3) US9046532B2 (pt)
EP (1) EP2419741B1 (pt)
JP (1) JP5650718B2 (pt)
CN (2) CN105334330A (pt)
CY (1) CY1122202T1 (pt)
DK (1) DK2419741T3 (pt)
ES (1) ES2751105T3 (pt)
HK (1) HK1221766A1 (pt)
HR (1) HRP20191862T1 (pt)
HU (1) HUE046182T2 (pt)
LT (1) LT2419741T (pt)
PL (1) PL2419741T3 (pt)
PT (1) PT2419741T (pt)
SI (1) SI2419741T1 (pt)
WO (1) WO2010118855A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9488659B2 (en) 2012-04-12 2016-11-08 B.R.A.H.M.S. Gmbh Prognosis of adverse events in patients with suspected chronic heart failure
CN105528511A (zh) * 2014-10-25 2016-04-27 潘一琦 一种远程诊疗对比式问诊方法及其系统
CN107301319B (zh) * 2017-06-26 2021-02-26 济南市儿童医院 儿科临床及科研中抗菌药物使用危险评估系统
CN111656189A (zh) * 2017-12-20 2020-09-11 B.R.A.H.M.S有限公司 基于合并症患者的降钙素原的抗生素疗法指导
EP3502706A1 (en) * 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5314804A (en) * 1992-03-24 1994-05-24 Serim Research Corporation Test for Helicobacter pylori
DE19600875C1 (de) * 1996-01-12 1997-06-26 Brahms Diagnostica Gmbh Diagnostisches Verfahren zur Bestimmung der Ätiologie entzündlicher Prozesse
ATE395364T1 (de) * 1999-12-22 2008-05-15 Dade Behring Marburg Gmbh Gegen procalcitonin gerichtete antikörper, ihre herstellung und verwendung
WO2003016910A1 (en) * 2001-08-20 2003-02-27 Biosite, Inc. Diagnostic markers of stroke and cerebral injury and methods of use thereof
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
DE102005034174A1 (de) * 2005-07-21 2007-02-08 B.R.A.H.M.S Ag Liquordiagnostisches in vitro Verfahren zur Diagnose von Demenz-Erkrankungen und neuroinflammatorischen Erkrankungen
FR2894675B1 (fr) * 2005-12-14 2008-06-27 Assist Publ Hopitaux De Paris Distinction des meningites bacteriennes et virales
DE102006046996A1 (de) * 2006-10-01 2008-04-03 Brahms Aktiengesellschaft Diagnose von Infektionen oder Entzündungserkrankungen der Atemwege und Lunge assoziiert mit Herzinsuffizienz
CN110346577A (zh) 2007-08-03 2019-10-18 B.R.A.H.M.S 有限公司 降钙素原（pct）在患原发性非传染疾病的患者的风险分级和预后中的应用

Also Published As

Publication number Publication date
CN102395888A (zh) 2012-03-28
CN102395888B (zh) 2017-05-03
JP5650718B2 (ja) 2015-01-07
CY1122202T1 (el) 2020-11-25
CN105334330A (zh) 2016-02-17
DK2419741T3 (da) 2019-11-04
WO2010118855A1 (en) 2010-10-21
HUE046182T2 (hu) 2020-02-28
HK1221766A1 (zh) 2017-06-09
US20120100635A1 (en) 2012-04-26
ES2751105T3 (es) 2020-03-30
PL2419741T3 (pl) 2020-01-31
JP2012523573A (ja) 2012-10-04
US9810699B2 (en) 2017-11-07
US20180052179A1 (en) 2018-02-22
HRP20191862T1 (hr) 2019-12-27
US9046532B2 (en) 2015-06-02
LT2419741T (lt) 2019-11-11
EP2419741B1 (en) 2019-07-31
US20150247871A1 (en) 2015-09-03
SI2419741T1 (sl) 2019-12-31
EP2419741A1 (en) 2012-02-22

Similar Documents

Publication Publication Date Title
HK1258617A1 (zh) 雙重機制抑制劑用於治療疾病
IL259475A (en) Combined therapy for the treatment of diabetes
HRP20181608T1 (hr) Korištenje inhibitora pde7 u liječenju bolesti kretanja
HK1221766A1 (zh) 通過測定降鈣素原水平對在原發性非感染性疾病患者中的抗生素治療進行風險評估
EP2504036A4 (en) GRADED COMPRESSION ELEMENT FOR THE TREATMENT OF CIRCULATORY DISORDERS
IL217901B (en) Use of laquinimod or a laquinimod salt in the manufacture of a drug for the treatment of bdnf-related diseases
IL195135A0 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
ZA201203808B (en) Combination for the treatment of radiation-or chemotherapy-induced mucositis
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
EP2544686A4 (en) COMBINED METHODS FOR THE TREATMENT OF DISEASES
HK1203190A1 (en) Compounds for use in imaging, diagnosing and or treatment of diseases of the central nervous system
EP2701702A4 (en) OXYMETAZOLINE FOR THE TREATMENT OF ANO-RECTAL DISEASES
IL219050A0 (en) Pharmaceutical composition for the treatment of bladder disorders
ZA201306759B (en) Compounds for use in imaging,diagnosing and/or treatment of diseases of the central nervous system
IL228973A (en) Oxymetazoline for the treatment of rectal disorders
GB201014519D0 (en) In vivo screened models for treatment of isoQC-related disorders
ZA200808104B (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders